By Itself - Mr.NA DOES NOT Vaccinate Against Super-Covid!!! But....,

nature | These jokers created some super-covid from the worst strains of existing covid variants. (Gain of Function Research)  It’s virological and immunological <s>dual use bioweapons</s> research.  Hope none gets out of the NYC lab where they created it over a year ago. 

They then tested antibodies created from a natural Covid-19 infection - and - antibodies created by someone with an mRNA vaccine against this “gain of function” super strain of Covid-19. The super Covid was resistant to both types of antibodies. However, antibodies from someone who both was infected and recovered from a Covid-19 infection AND received an mRNA vaccination defeated the super strain of Covid-19.

 

The number and variability of the neutralizing epitopes targeted by polyclonal antibodies in SARS-CoV-2 convalescent and vaccinated individuals are key determinants of neutralization breadth and the genetic barrier to viral escape^1–4. Using HIV-1 pseudotypes and plasma-selection experiments with vesicular stomatitis virus/SARS-CoV-2 chimeras⁵, we show that multiple neutralizing epitopes, within and outside the receptor binding domain (RBD), are variably targeted by human polyclonal antibodies. Antibody targets coincide with spike sequences that are enriched for diversity in natural SARS-CoV-2 populations. By combining plasma-selected spike substitutions, we generated synthetic ‘polymutant’ spike protein pseudotypes that resisted polyclonal antibody neutralization to a similar degree as circulating variants of concern (VOC). By aggregating VOC-associated and antibody-selected spike substitutions into a single polymutant spike protein, we show that 20 naturally occurring mutations in SARS-CoV-2 spike are sufficient to generate pseudotypes with near-complete resistance to the polyclonal neutralizing antibodies generated by convalescents or mRNA vaccine recipients. Strikingly, however, plasma from individuals who had been infected and subsequently received mRNA vaccination, neutralized pseudotypes bearing this highly resistant SARS-CoV-2 polymutant spike, or diverse sarbecovirus spike proteins. Thus, optimally elicited human polyclonal antibodies against SARS-CoV-2 should be resilient to substantial future SARS-CoV-2 variation and may confer protection against potential future sarbecovirus pandemics.